AHL
CLDX icon

Abel Hall LLC’s Celldex Therapeutics CLDX Stock Holding History

Abel Hall LLC’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+5,838
New +$189K 0.04% 687

Other funds holding CLDX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MCP
Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Abel Hall LLC's CLDX Position: Q2 2026 in Review

Abel Hall LLC opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 5,838 shares worth $217K. The stake represents 0.04% of the portfolio and ranks #687 among its holdings.

37 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Abel Hall LLC held 5,838 shares of Celldex Therapeutics worth $217K as of Q2 2026.
  • Celldex Therapeutics was a new Abel Hall LLC position in Q2 2026.
  • Celldex Therapeutics made up 0.04% of Abel Hall LLC's portfolio in Q2 2026, its #687 holding.
  • 37 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.